welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)
study id #: NCT00140894
condition: Adenomatous Polyposis Coli
A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.
Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks
Drug: Comparator: placebo / Duration of Treatment: 24 weeks
start date: March 2003
estimated completion: Not Available
last updated: September 29, 2017
phase of development: Phase 4
size / enrollment: 62
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
- Number and average size of rectal polyps
- Safety and tolerability
- Number and average size of duodenal polyps
- Proportions of patients with improved overall colon rating
- Males or females at least 18 years of age with familial adenomatous polyposis.
expertly curated content related to this topic
Is Diverting Ileostomy Necessary in Stapled Ileoanal Pouch?Total proctocolectomy with ileal pouch a...
Non-Invasive Prediction of Colorectal NeoplasiaHypothesis:The Adnab-9 antigen is a ...
Significantly Increased Pregnancy Rates After Laparoscopic Restorative Proctocolectomy: A Cross-sectional StudyOBJECTIVE: To assess the impact of a la...
18F-FES PET/CT in Imaging Patients With Desmoid TumorsThis pilot clinical trial studies fluori...
Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatou...Exisulind (sulindac sulfone; FGN-1), a m...
my stoma bag storyLeanne Hammond My story; life isn't s...
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPAThis purpose of this study is to investi...